Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06305754
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-03-05
Brief Title:
Sacituzumab Tirumotecan MK-2870 Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor EGFR-Mutated Advanced Nonsquamous Non-small Cell Lung Cancer NSCLC and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors MK-2870-009
Sponsor:
Organization:
Merck Sharp Dohme LLC